CN102670740A - Drug composition for treating soft tissue injuries and preparation process thereof - Google Patents
Drug composition for treating soft tissue injuries and preparation process thereof Download PDFInfo
- Publication number
- CN102670740A CN102670740A CN201210169241XA CN201210169241A CN102670740A CN 102670740 A CN102670740 A CN 102670740A CN 201210169241X A CN201210169241X A CN 201210169241XA CN 201210169241 A CN201210169241 A CN 201210169241A CN 102670740 A CN102670740 A CN 102670740A
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- soft tissue
- parts
- hirudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a drug composition for treating soft tissue injuries. Main pharmacodynamic raw materials of the drug composition comprises, by weight, 200 to 300 parts of rhubarb, 10 to 100 parts of frankincense, 10 to 100 parts of myrrh, 50 to 150 parts of ground beetles, 50 to 150 parts of leeches, 50 to 150 parts of pseudo-ginseng, 10 to 150 parts of house lizards, 10 to 100 parts of lumbricus and 200 to 300 parts of trichosanthes roots. The preparation process includes the steps of weighing out all pharmacodynamic raw materials according to the formula, mixing all pharmacodynamic raw materials through crushing, aqueous extraction concentration or a combination of crushing and aqueous extraction concentration, and obtaining the drug composition. The drug composition can promote blood circulation to remove blood stasis, can activate meridians to relieve pain, and is applicable to symptoms such as local swelling congestion, pain and dysfunction caused by traumas such as injuries from falls, fractures, contusions and strains and soft tissue contusion.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, especially a kind of is the pharmaceutical preparation that is used for blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain that raw material is processed with the vegetable Chinese herbal medicine, is particularly useful for sports medical science; The invention still further relates to the method for preparing of this pharmaceutical preparation.
Background technology
Acute and chronic soft tissue is common clinical, frequently-occurring disease; Medicine commonly used at present can not well be subsided a swelling, pain relieving, can not accelerate damaged tissue as scheduled and recover, and hemorrhage absorption is slower; Time and injury repairing in onset are all longer on the time, are unfavorable for patient's rehabilitation as early as possible.
Summary of the invention
The technical problem that the present invention will solve provides a kind of pharmaceutical composition of treating soft tissue injury, can blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, be used for diseases such as local swelling congestion that wounds such as traumatic injury, soft tissue contusion cause, pain, dysfunction; For this reason, the present invention provides this preparation of drug combination method simultaneously.
For solving the problems of the technologies described above, the technical scheme that the present invention taked is following.
A kind of pharmaceutical composition of treating soft tissue injury, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 200～300; Olibanum 10～100; Myrrha 10～100; Eupolyphaga Seu Steleophaga 50～150; Hirudo 50～150; Radix Notoginseng 50～150; Gekko Swinhonis 10～150; Pheretima 10～100; Radix Trichosanthis 200～300.
As a kind of optimal technical scheme of the present invention, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 260～280; Olibanum 34～38; Myrrha 34～38; Eupolyphaga Seu Steleophaga 51～57; Hirudo 51～57; Radix Notoginseng 51～57; Gekko Swinhonis 34～38; Pheretima 34～38; Radix Trichosanthis 200～230.
As a kind of optimal technical scheme of the present invention, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 270; Olibanum 36; Myrrha 36; Eupolyphaga Seu Steleophaga 54; Hirudo 54; Radix Notoginseng 54; Gekko Swinhonis 36; Pheretima 36; Radix Trichosanthis 216.
As a kind of optimal technical scheme of the present invention, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 280; Olibanum 34; Myrrha 34; Eupolyphaga Seu Steleophaga 52; Hirudo 57; Radix Notoginseng 56; Gekko Swinhonis 37; Pheretima 35; Radix Trichosanthis 220.
The preparation of drug combination method of above-mentioned treatment soft tissue injury: take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, through pulverize, the water concentration contracts or the two bonded mode with each pharmacodynamic raw materials mixing, promptly get.
As a kind of optimal technical scheme of above-mentioned method for preparing, its step comprises:
A, take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, wherein Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, 75 ℃～85 ℃ dryings of Pheretima five tastes medical material are ground into fine powder; Olibanum, 55 ℃～65 ℃ dryings of Myrrha are ground into fine powder;
B, Radix Et Rhizoma Rhei, Radix Trichosanthis add 9～11 times of water gagings and decoct, and decocting liquid filters, and filtrating is concentrated into the clear paste that relative density is 1.15g/ml～1.20g/ml;
Add the fine powder of Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, Pheretima five tastes medical material in C, the step B gained clear paste, mix thoroughly, 75 ℃～85 ℃ dryings;
D, the good creme of step C drying are ground into middle powder, add Olibanum, do not have medicated powder, sieve, and mixing promptly gets.
As a kind of optimal technical scheme of above-mentioned method for preparing, the step D products obtained therefrom Capsules of packing into, every dress 0.4g gets product.
As a kind of optimal technical scheme of above-mentioned method for preparing, among the step B, Radix Et Rhizoma Rhei, Radix Trichosanthis add 9～11 times of water gagings and decoct 1～3 time, decoct collecting decoction continued subsequent step altogether 2 hours～4 hours.
A kind of optimal technical scheme as above-mentioned method for preparing takes by weighing each pharmacodynamic raw materials according to above-mentioned prescription, is ground into fine powder, sieves, and mixing promptly gets.
As a kind of optimal technical scheme of above-mentioned method for preparing, the products obtained therefrom Capsules of packing into, every dress 0.4g gets product.
Adopt the beneficial effect that technique scheme produced to be:
Function of the present invention cures mainly: blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain are used for diseases such as local swelling congestion that wounds such as traumatic injury, soft tissue contusion cause, pain, dysfunction; Be particularly useful for sports medical science.This present invention pharmaceutical composition external application, interior with the acute and chronic soft tissue injury of treatment; Improving determined curative effect aspect the symptoms such as pain, swelling, ecchymosis and handicapped scoring and pain, dysfunction; Can accelerate the damaged tissue reparation as scheduled; Quickening hemorrhage absorption, is a kind of worth pure Chinese medicinal preparation of wideling popularize clinically.
Radix Et Rhizoma Rhei blood circulation promoting and blood stasis dispelling in the side, Olibanum, the Myrrha blood circulation promoting and blood stasis dispelling promoting the circulation of QI to relieve pain of holding concurrently, the three mutually 5, are monarch drug altogether; Eupolyphaga Seu Steleophaga, Hirudo removing blood stasis, reunion of fractured tendons and bones, the pain relieving of curing the wound, pseudo-ginseng blood-circulation-invigovating analgesic therapy, removing stasis to stop bleeding, the three is the effect of 5 enhancing monarch drug blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain mutually, is to be ministerial drug; Gekko Swinhonis, Pheretima detoxicating and resolving stagnation of pathogens, removing obstruction in the collateral to relieve pain are good at walking key into network, and Radix Trichosanthis had both been gone into blood system and helped all medicines and dissipating blood stasis and reducing the stagnation, again can clearing heat and moistening dryness, and the three 5 is to be adjuvant mutually.All medicines share, and amount to the effect of blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain.And have no adverse reaction through this preparation of clinical verification, toxicity is less, and is safe and reliable.
Following Test Example further illustrates beneficial effect of the present invention.Wherein employed outturn sample of the present invention is the capsule product of following embodiment 1 preparation.Usage and dosage of the present invention is during human trial: oral, and each 5, every day 3 times; Two weeks of continuous use are a course of treatment.
Test Example (1), acute toxicity test in mice
Herbal pharmacology teaching and research room of the college of traditional Chinese medicine of Hebei Medical University is studied the acute toxicity test in mice of these article; The result shows: 20 of Kunming strain mices; Per os is gastric infusion once-a-day, when dosage is 14.4g/kg (be equivalent to clinical consumption 144 times), observes a week continuously; Mice does not have death, does not find any untoward reaction.According to " study of tcm new drug guide " (94-0198) chapter 2 The acute toxicity tests evaluation criterion, these article oral administration acute toxicity is nontoxic basically.
Test Example (2), Pharmacodynamic test of active extract.
Herbal pharmacology teaching and research room of the college of traditional Chinese medicine of Hebei Medical University has carried out experimentation to the drug effect of these article; The result shows that pharmaceutical composition of the present invention (0.7g/kg, 1.4g/kg, 2.8g/kg) can suppress rat paw edema due to the carrageenin, has certain antiinflammatory action; Pharmaceutical composition of the present invention (0.9g/kg, 1.8g/kg, 3.6g/kg) can suppress xylene induced mice ear swelling, improves mice hot plate method pain threshold, and 0.6% acetic acid induced mice pain is had significant analgesia role.
Experimental example (3), rat long term toxicity test.
Herbal pharmacology teaching and research room of the college of traditional Chinese medicine of Hebei Medical University has carried out the rat long term toxicity test to these article.The result shows; The oral suspension administration; Dosage 1.25g/kg, 2.5g/kg, 5g/kg (be equivalent to clinical application 12.5 times, 25 times, 50 times), result show, pharmaceutical composition of the present invention (1g/kg, 2g/kg, 4g/kg) does not all have obvious influence to the general situation body weight of rat, hematological indices, ten biochemical indicators and main organs coefficient; Each internal organs naked eyes and mirror are observed down, also do not have obvious pathological change.Show that this medicine does not have the overt toxicity reaction, explain that the medication under this experiment condition of this product is a basic security, pointing out this product under prescribed dose, to use is possible safe and reliable.
Test Example (4), clinical observation on the therapeutic effect.
Pharmaceutical composition of the present invention has the effect of blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain.For clinical efficacy and the safety of verifying medicine composite for curing soft tissue injury of the present invention; Shijiazhuang City, Hebei Province safety hospital adopts the observational technique of contrast at random; Carry out the clinical contrast observation with the positive control drug notoginseng-containing tablet, tried case and be that to meet soft tissue injury diagnostic criteria, tcm diagnosis be the qi depression to blood stasis person and the case of signing Informed Consent Form.Test finished since year October in August, 2007 to 2007, accomplished clinical observation case 120 examples altogether, test group 60 examples wherein, matched group 60 examples.This group result of study shows that in the 120 routine cases, cure rate reaches 100%, and obvious effective rate is 99% in the recent period.The treatment group pain improvement situation of using pharmaceutical composition of the present invention is more or less the same with the matched group effect of using notoginseng-containing tablet; Pain is improved situation does not also have obvious difference; Swelling and handicapped improvement situation are better than notoginseng-containing tablet effect, and the ecchymosis improvement obviously is better than matched group.It is thus clear that pharmaceutical composition of the present invention can obviously play the curative effect of vital energy regualting and blood circulation-promoting, reducing swelling and alleviating pain, can obviously improve swelling and pain symptom.The short term effect of using medicine composite for curing soft tissue injury of the present invention is remarkable, and late result awaits further observation.
The specific embodiment
Following examples have specified the present invention.Various raw material used in the present invention and items of equipment are conventional commercially available prod, all can buy directly through market to obtain.
The instructions of taking of pharmaceutical composition of the present invention is: oral, one time 3～5, every the dress 0.4g, 3 times on the one; Cold, the irritable food of diet.
Relate to notions such as " coarse powder ", " fine powder ", " fine powder " among the following embodiment, its concrete implication is following:
1. powder grades:
2. medicine screening etc.:
Embodiment 1
A kind of pharmaceutical composition of treating soft tissue injury, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 270; Olibanum 36; Myrrha 36; Eupolyphaga Seu Steleophaga 54; Hirudo 54; Radix Notoginseng 54; Gekko Swinhonis 36; Pheretima 36; Radix Trichosanthis 216.Its preparation process comprises:
A, take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, wherein are Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, 80 ℃ of dryings of Pheretima five tastes medical material ground into fine powder (specific to how many orders?); Olibanum, 60 ℃ of dryings of Myrrha are ground into fine powder;
B, Radix Et Rhizoma Rhei, Radix Trichosanthis add 10 times of water gagings and decoct 2 times, and 2 hours for the first time, 1.5 hours for the second time, collecting decoction filtered, and filtrating is concentrated into the clear paste that relative density is 1.15g/ml～1.20g/ml (50～60 ℃);
Add the fine powder of Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, Pheretima five tastes medical material in C, the step B gained clear paste, mix thoroughly, 80 ℃ of dryings;
D, the good creme of step C drying are ground into middle powder, add Olibanum, do not have medicated powder, sieve mixing;
E, the step D products obtained therefrom 0# Capsules of packing into, every dress 0.4g gets product.
Embodiment 2
A kind of pharmaceutical composition of treating soft tissue injury, the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 280; Olibanum 34; Myrrha 34; Eupolyphaga Seu Steleophaga 52; Hirudo 57; Radix Notoginseng 56; Gekko Swinhonis 37; Pheretima 35; Radix Trichosanthis 220.Its preparation process comprises:
A, take by weighing each pharmacodynamic raw materials, be ground into fine powder, sieve mixing according to above-mentioned prescription;
B, the products obtained therefrom 0# Capsules of packing into, every dress 0.4g gets product.
In addition; Dried cream, thick paste or the mixture of powders of the above embodiment of the present invention preparation can add Mel or other pharmaceutically acceptable excipient, process pill or other acceptable clinically granules, drop pill, tablet, capsule, suspensoid, oral liquid etc.
Foregoing description only proposes as the enforceable technical scheme of the present invention, not as the single restrictive condition to its technical scheme itself.
Claims (10)
1. a pharmaceutical composition of treating soft tissue injury is characterized in that the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 200～300; Olibanum 10～100; Myrrha 10～100; Eupolyphaga Seu Steleophaga 50～150; Hirudo 50～150; Radix Notoginseng 50～150; Gekko Swinhonis 10～150; Pheretima 10～100; Radix Trichosanthis 200～300.
2. the pharmaceutical composition of treatment soft tissue injury according to claim 1 is characterized in that: the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 260～280; Olibanum 34～38; Myrrha 34～38; Eupolyphaga Seu Steleophaga 51～57; Hirudo 51～57; Radix Notoginseng 51～57; Gekko Swinhonis 34～38; Pheretima 34～38; Radix Trichosanthis 200～230.
3. the pharmaceutical composition of treatment soft tissue injury according to claim 2 is characterized in that: the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 270; Olibanum 36; Myrrha 36; Eupolyphaga Seu Steleophaga 54; Hirudo 54; Radix Notoginseng 54; Gekko Swinhonis 36; Pheretima 36; Radix Trichosanthis 216.
4. the pharmaceutical composition of treatment soft tissue injury according to claim 2 is characterized in that: the main pharmacodynamics raw material of processing this pharmaceutical composition by ratio of weight and the number of copies is: Radix Et Rhizoma Rhei 280; Olibanum 34; Myrrha 34; Eupolyphaga Seu Steleophaga 52; Hirudo 57; Radix Notoginseng 56; Gekko Swinhonis 37; Pheretima 35; Radix Trichosanthis 220.
5. the preparation of drug combination method of above-mentioned treatment soft tissue injury is characterized in that: take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, through pulverize, the water concentration contracts or the two bonded mode with each pharmacodynamic raw materials mixing, promptly get.
6. method for preparing according to claim 5, its characterization step comprises:
A, take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, wherein Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, 75 ℃～85 ℃ dryings of Pheretima five tastes medical material are ground into fine powder; Olibanum, 55 ℃～65 ℃ dryings of Myrrha are ground into fine powder;
B, Radix Et Rhizoma Rhei, Radix Trichosanthis add 9～11 times of water gagings and decoct, and decocting liquid filters, and filtrating is concentrated into the clear paste that relative density is 1.15g/ml～1.20g/ml;
Add the fine powder of Eupolyphaga Seu Steleophaga, Hirudo, Radix Notoginseng, Gekko Swinhonis, Pheretima five tastes medical material in C, the step B gained clear paste, mix thoroughly, 75 ℃～85 ℃ dryings;
D, the good creme of step C drying are ground into middle powder, add Olibanum, do not have medicated powder, sieve, and mixing promptly gets.
7. method for preparing according to claim 6 is characterized in that: the step D products obtained therefrom Capsules of packing into, every dress 0.4g gets product.
8. method for preparing according to claim 6 is characterized in that: among the step B, Radix Et Rhizoma Rhei, Radix Trichosanthis add 9～11 times of water gagings and decoct 1～3 time, decoct collecting decoction continued subsequent step altogether 2 hours～4 hours.
9. method for preparing according to claim 5 is characterized in that: take by weighing each pharmacodynamic raw materials according to above-mentioned prescription, be ground into fine powder, sieve, mixing promptly gets.
10. method for preparing according to claim 9 is characterized in that: the products obtained therefrom Capsules of packing into, every dress 0.4g gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210169241.XA CN102670740B (en) | 2012-05-28 | 2012-05-28 | Drug composition for treating soft tissue injuries and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210169241.XA CN102670740B (en) | 2012-05-28 | 2012-05-28 | Drug composition for treating soft tissue injuries and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102670740A true CN102670740A (en) | 2012-09-19 |
| CN102670740B CN102670740B (en) | 2014-01-15 |
Family
ID=46803726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210169241.XA Active CN102670740B (en) | 2012-05-28 | 2012-05-28 | Drug composition for treating soft tissue injuries and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670740B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125538A (en) * | 2017-06-15 | 2019-01-04 | 洛阳士雄聚元医疗集团股份有限公司 | A kind of oral traditional Chinese medicine composition for treating soft tissue bruise |
| CN113827557A (en) * | 2021-11-18 | 2021-12-24 | 河南中医药大学 | Traditional Chinese medicine ointment for preventing and treating radiodermatitis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1438006A (en) * | 2003-03-13 | 2003-08-27 | 李根喜 | medicine for treating orthopedic disease |
| WO2003099302A1 (en) * | 2002-05-24 | 2003-12-04 | Turispharma S.R.L. | A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere |
| CN101015670A (en) * | 2007-02-13 | 2007-08-15 | 李翠梅 | Preparation process of traditional Chinese medicine lotion for treating closed trauma |
| CN101961146A (en) * | 2010-06-07 | 2011-02-02 | 江阴芗菲服饰有限公司 | Manufacturing method for sweaters with pocket suit |
| CN102283923A (en) * | 2011-08-02 | 2011-12-21 | 韩文政 | Blood circulation promoting and swelling and pain relieving powder for trauma |
-
2012
- 2012-05-28 CN CN201210169241.XA patent/CN102670740B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099302A1 (en) * | 2002-05-24 | 2003-12-04 | Turispharma S.R.L. | A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere |
| CN1438006A (en) * | 2003-03-13 | 2003-08-27 | 李根喜 | medicine for treating orthopedic disease |
| CN101015670A (en) * | 2007-02-13 | 2007-08-15 | 李翠梅 | Preparation process of traditional Chinese medicine lotion for treating closed trauma |
| CN101961146A (en) * | 2010-06-07 | 2011-02-02 | 江阴芗菲服饰有限公司 | Manufacturing method for sweaters with pocket suit |
| CN102283923A (en) * | 2011-08-02 | 2011-12-21 | 韩文政 | Blood circulation promoting and swelling and pain relieving powder for trauma |
Non-Patent Citations (1)
| Title |
|---|
| 王文燕: "外用中药分期治疗踝关节扭伤的临床研究", 《山东体育学报》, vol. 17, no. 3, 31 December 2001 (2001-12-31) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125538A (en) * | 2017-06-15 | 2019-01-04 | 洛阳士雄聚元医疗集团股份有限公司 | A kind of oral traditional Chinese medicine composition for treating soft tissue bruise |
| CN113827557A (en) * | 2021-11-18 | 2021-12-24 | 河南中医药大学 | Traditional Chinese medicine ointment for preventing and treating radiodermatitis |
| CN113827557B (en) * | 2021-11-18 | 2024-01-26 | 河南中医药大学 | Traditional Chinese medicine ointment for preventing and treating radiodermatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102670740B (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703692A (en) | Chinese medicinal preparation for treating bone fracture and preparation method thereof | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN1824009A (en) | Multipurpose medicinal composition capable of oral administration and external use | |
| CN102166277A (en) | Waist healing pill | |
| CN101537093A (en) | Chinese traditional medicine for preventing and curing osteoporosis and preparation method thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102670740B (en) | Drug composition for treating soft tissue injuries and preparation process thereof | |
| CN101239159B (en) | Chinese medicinal composition for treating rheumatoild disease and preparation thereof | |
| CN101239107A (en) | Chinese medicine capsule for treating hemifacial spasm | |
| CN103027978A (en) | Medicine composition for treating traumatic injury and preparation method of medicine composition | |
| CN101116674B (en) | Mongolian medicine for treating bone fracture | |
| CN1319574C (en) | Medicine for treating constipation | |
| CN102579610A (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN101983695A (en) | Traditional Chinese medicine composition for curing hemiplegia and preparation method thereof | |
| CN104107288A (en) | Sinew-relaxing collateral-activating pill | |
| CN102139005B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN102846741B (en) | Navel-applied plaster for treating sequelae of hemiplegia and preparation method thereof | |
| CN102614343A (en) | Medicament for treating dysmenorrhea | |
| CN101439106A (en) | Medicament for treating apoplexy | |
| CN102430096A (en) | Medicament for treating rheumatic or rheumatoid diseases | |
| CN102743531B (en) | Drug for treating cervical or lumbar diseases and preparation method thereof | |
| CN102552724A (en) | Chinese medicine composite for curing hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Feng Baoheng Inventor after: Ba Yingwei Inventor after: Niu Chaoxu Inventor after: Liu Hongliang Inventor after: Wang Jingming Inventor after: Wang Xudong Inventor after: Peng Xiaofei Inventor before: Huang Huaipeng Inventor before: Feng Baoheng Inventor before: Ba Yingwei Inventor before: Tao Jun Inventor before: Li Jinghan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HUANG HUAIPENG FENG BAOHENG BA YINGWEI TAO JUN LI JINGHAN TO: FENG BAOHENGBA YINGWEI NIU CHAOXU LIU HONGLIANG WANG JINGMING WANG XUDONG PENG XIAOFEI |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |